ABSTRACT Mycobacterium xenopi comprised 56% of all non-tuberculous mycobacteria isolated in the Brompton Hospital laboratory during six years. M xenopi alone was cultured from the sputum of 23 patients, whose clinical and bacteriological features are reviewed. Pulmonary disease was considered to be due to the organism present in 15 of these patients on the basis of strict criteria for a causal relationship. Radiographs of all these patients were consistent with mycobacterial disease, showing pulmonary cavitation in 11, apical shadowing in three, and upper lobe fibrosis in one. In nine patients the disease was chronic, progressing very slowly with longstanding respiratory symptoms and extensive radiographic abnormalities developing over many years (mean 19 years). In six patients the disease was subacute, being of recent onset with radiographic shadowing of limited extent. M xenopi was isolated as a saprophyte from four patients who had lung disease of known cause and single isolates were obtained from four patients who had no lung disease attributable to this organism. In vitro drug sensitivity tests showed the sputum cultures of 17 of 22 patients to be sensitive to two or more of the drugs rifampicin, isoniazid, and ethambutol. Response to chemotherapy was unpredictable and did not always correlate with the results of sensitivity tests. Of 11 patients treated with at least two drugs to which their organisms were sensitive, two remained sputum positive, one relapsed after 18 months of chemotherapy, and eight have remained sputum negative during a minimum of three years' follow-up.
Mycobacterium xenopi was first isolated by Schwabacher in 1959' from a cutaneous lesion of a South African toad, Xenopus laevis. The organism is a non-chromogenic acid-fast bacillus (Runyon group III) and its bacteriological characteristics have been well defined.2 The role of this organism as a cause of pulmonary disease is not well established. Strains of M xenopi have been isolated from the sputum of patients in many parts of the world but only 50 cases have been reported in whom pulmonary disease has been ascribed to it.3 We have reviewed the records of patients from whose sputum M xenopi was grown in the Brompton Hospital laboratory to determine whether their pulmonary disease could be attributed to this organism. Details of their clinical and bacteriological features and response to treatment are presented.
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Methods
During the six years 1972-8 non-tuberculous mycobacteria were isolated from the sputum of 48 patients and M xenopi was found in 27 (56%) of them (table 1) . This paper is concerned only with the 23 patients whose sputum contained M xenopi alone. Identification of the organism and sensitivity testing were performed by the standard techniques used in our laboratory.4
Results

Radiology
All 23 patients had abnormal chest radiographs. 1213 but information about response to chemotherapy is lacking. In our series 17 of the 22 patients with sensitivity results had sputum cultures sensitive to at least two of the drugs rifampicin, ethambutol, and isoniazid. Sputum conversion was achieved in nine of the 11 patients treated (82%) and in all nine patients the chemotherapy regimen included at least two drugs to which the organism was sensitive. One patient, however, relapsed and two failed to respond despite having drugs to which the organisms were sensitive in vitro. Our experience therefore suggests that while in vitro drug resistance is not a major problem with this organism the clinical response is unpredictable. With one exception the patients received chemotherapy for at least 18 months and, in the absence of information about the efficacy of chemotherapy of shorter duration, it would seem reasonable to recommend a treatment period of 18-24 months.
It would be difficult to obtain enough patients for a prospective trial of chemotherapy in this rare disease. It is therefore important that as much information as possible is collected about the clinical fea-tures and treatment of these infections so that a more rational approach to diagnosis and management may be developed.
